Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Last winter, I was speculating that Ipsen would be a good partner with Spectrum in a possible licencing deal for apaziquone as result of Ipsen's interest in that space even though at the time they just make a large deal for cabozantinib. So people didn't think my speculation had any merit since Ipsen had a lot less cash to play around with. Lo and behold they made a 575M in cash deal for US rights (w a possibility of another 450M) for Merrmack Pharma's pancreatic cancer drug Onivyde. Onivyde has only 60M per yr in sales. Damn what could have been if apaziquone was approved. Oh well.